Quebec biosimilars announcement
The transition to a biosimilar can take place safely under the right conditions, improve access to treatment while also providing savings that can be reinvested into expanded healthcare. The Arthritis Society’s priority is to ensure that people living with arthritis have access to the life-changing treatments and information they need. We are ready to review the policy the Quebec government announced yesterday regarding its biosimilars initiative and provide any necessary feedback. We look forward to working with them to ensure that this transition is seamless for patients and puts their needs and experiences front and centre.
Read our full position on biosimilars [PDF].
Back to News